RxDoctor Payments Data

McHale Anderson, MD

Cardiovascular Disease · Golden, CONPI 1003312711

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,413 of the $3,834 with a category attached, or 89.0%. It is spread thinly across 25 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,748, 3.7 times the $478 reported in 2021.

$3,834in general payments, 2019–2025

Across 74 payments — averaging $51.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$826
  • E.r. Squibb & Sons, L.L.C.$347
  • Boston Scientific$321
  • Heartflow, Inc.$315
  • Novo Nordisk$271
  • Abiomed$267
  • plus $1K from 19 others
$7,443in research payments, 2019–2025

Across 2 payments — averaging $3721.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$7K

What the payments were for

  • Food & beverage$3,41389%
  • Education$3459%
  • Gifts$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,834 in reported general payments places this provider in the 65th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$25,871
Medicare patients
172
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Furosemide13$83
Spironolactone13$77
Metoprolol Succinate13$65
Atorvastatin Calcium16$59

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Golden

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →